Innoviva Shares Outstanding 2010-2024 | INVA
Innoviva shares outstanding from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Innoviva Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
87 |
| 2022 |
95 |
| 2021 |
94 |
| 2020 |
114 |
| 2019 |
113 |
| 2018 |
113 |
| 2017 |
120 |
| 2016 |
123 |
| 2015 |
115 |
| 2014 |
112 |
| 2013 |
102 |
| 2012 |
91 |
| 2011 |
82 |
| 2010 |
72 |
| 2009 |
63 |
Innoviva Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-06-30 |
63 |
| 2024-03-31 |
85 |
| 2023-12-31 |
87 |
| 2023-09-30 |
86 |
| 2023-06-30 |
65 |
| 2023-03-31 |
90 |
| 2022-12-31 |
95 |
| 2022-09-30 |
96 |
| 2022-06-30 |
96 |
| 2022-03-31 |
94 |
| 2021-12-31 |
94 |
| 2021-09-30 |
82 |
| 2021-06-30 |
101 |
| 2021-03-31 |
114 |
| 2020-12-31 |
114 |
| 2020-09-30 |
114 |
| 2020-06-30 |
114 |
| 2020-03-31 |
114 |
| 2019-12-31 |
113 |
| 2019-09-30 |
113 |
| 2019-06-30 |
113 |
| 2019-03-31 |
113 |
| 2018-12-31 |
113 |
| 2018-09-30 |
113 |
| 2018-06-30 |
113 |
| 2018-03-31 |
114 |
| 2017-12-31 |
120 |
| 2017-09-30 |
120 |
| 2017-06-30 |
120 |
| 2017-03-31 |
120 |
| 2016-12-31 |
123 |
| 2016-09-30 |
122 |
| 2016-06-30 |
124 |
| 2016-03-31 |
113 |
| 2015-12-31 |
115 |
| 2015-09-30 |
116 |
| 2015-06-30 |
115 |
| 2015-03-31 |
115 |
| 2014-12-31 |
112 |
| 2014-09-30 |
113 |
| 2014-06-30 |
111 |
| 2014-03-31 |
110 |
| 2013-12-31 |
102 |
| 2013-09-30 |
106 |
| 2013-06-30 |
98 |
| 2013-03-31 |
96 |
| 2012-12-31 |
96 |
| 2012-09-30 |
95 |
| 2012-06-30 |
89 |
| 2012-03-31 |
92 |
| 2011-12-31 |
82 |
| 2011-09-30 |
82 |
| 2011-06-30 |
82 |
| 2011-03-31 |
81 |
| 2010-12-31 |
72 |
| 2010-09-30 |
74 |
| 2010-06-30 |
73 |
| 2010-03-31 |
65 |
| 2009-12-31 |
63 |
| 2009-09-30 |
63 |
| 2009-06-30 |
63 |
| 2009-03-31 |
62 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.259B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
